Tango Therapeutics (TNGX) Gains from Investment Securities (2020 - 2026)
Tango Therapeutics (TNGX) recorded quarterly Gains from Investment Securities of $828941.0 in Q1 2026, up 4262.85% quarter-over-quarter from $19000.0 in Q4 2025, and up 207.12% on a YoY basis from $269912.0 in Q1 2025.
Tango Therapeutics (TNGX) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Tango Therapeutics' Gains from Investment Securities history runs 7 years deep, the most recent figure standing at $828941.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 207.12% year-over-year to $828941.0; the TTM figure through Mar 2026 stood at $828941.0 (up 207.12% YoY), while the FY2025 annual figure was $20.5 million, up 4.34% from the prior year.
- Gains from Investment Securities was $828941.0 for Q1 2026 at Tango Therapeutics, up from $19000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $23.7 million in Q2 2025 to a low of -$64000.0 in Q4 2023.
- Historically, Gains from Investment Securities has averaged $5.0 million across 5 years, with a median of $577181.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities jumped 5033.27% in 2022, then tumbled 775.0% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$59000.0 in 2022, then declined by 8.47% to -$64000.0 in 2023, then jumped by 115.62% to $10000.0 in 2024, then surged by 90.0% to $19000.0 in 2025, then surged by 4262.85% to $828941.0 in 2026.
- The last three Gains from Investment Securities figures came in at $828941.0 (Q1 2026), $19000.0 (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 828,941.00 |
| Mar 31, 2026 | 828,941.00 |
| Dec 31, 2025 | 19,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Sep 30, 2025 | 1.29 Mn |
| Sep 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | 23.73 Mn |
| Jun 30, 2025 | 23.73 Mn |
| Mar 31, 2025 | 269,912.00 |
| Mar 31, 2025 | 269,912.00 |
| Dec 31, 2024 | 10,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Sep 30, 2024 | 19.82 Mn |
| Sep 30, 2024 | 19.82 Mn |
| Jun 30, 2024 | 4.78 Mn |
| Jun 30, 2024 | 4.78 Mn |
| Mar 31, 2024 | -35,000.00 |
| Mar 31, 2024 | -35,000.00 |
| Dec 31, 2023 | -64,000.00 |
| Dec 31, 2023 | -64,000.00 |